Because abnormal cytoplasmic DA accumulation also likely contributes to the development of Parkinson’s disease [22], the potential of MPD-induced increases in vesicular DA sequestration (caused by vesicle trafficking in the cytoplasmic vesicles and by kinetic upregulation of VMAT-2 in the membrane-associated vesicles) to attenuate the disease’s progression merits further investigation; as suggested by findings that MPD treatment improves motor function in Parkinson’s patients [9]. Here, SLC18A2 is linked to Parkinson disease.